<DOC>
	<DOC>NCT01698476</DOC>
	<brief_summary>The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate together with standard anti-tuberculosis treatment to significantly improve clinical recovery among patients with untreated, active pulmonary tuberculosis.</brief_summary>
	<brief_title>Immune Reconstitution in Tuberculosis Disease</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>HIV negative patients, adult patients &gt;18 years who has not started antiTB therapy. Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputumnegative clinical TB cases (defined according to the WHO 2006 criteria for sputum smearnegative TB ie. clinical symptoms of TB, chest Xray findings and response to standard treatment). Patients who have already started treatment with antiTB drugs for more that 5 days. HIVpositive patients. History of antiTB treatment in the past 2 years. Local extrapulmonary TB in the absence of lung manifestations. Hypercalcaemia (serum calcium &gt; 3 mmol/L) identified at baseline. Pregnant and breast feeding women. Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pulmonary TB</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>antimicrobial peptides</keyword>
	<keyword>immune response</keyword>
</DOC>